Tilrekimig

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

AsthmaCOPD

161 competitors in Asthma

#DrugCompanyPhaseTrials

1

Tilrekimig

Pfizer

Phase 3

22

Celexa

AbbVie

Preclinical

13

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

15

DUPIXENT

Regeneron

Preclinical

16

Paracetamol

GSK

Preclinical

17

Blood Withdrawn

Emergent BioSolutions

Preclinical

18

Aclidinium Bromide

AstraZeneca

Preclinical

—9

Atrovent

Boehringer Ingelheim

Preclinical

210

Lexapro

SShirley Ryan AbilityLab

Preclinical

1Show 16 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Asthma2 trials

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS WITH SEVERE ASTHMA

Recruiting·Pfizer·Phase 3·NCT07772921·1,100 enrolled

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS WITH SEVERE ASTHMA

Recruiting·Pfizer·Phase 3·NCT07869043·1,100 enrolled

Atopic Dermatitis2 trials

A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, ACTIVE- AND PLACEBO-CONTROLLED PHASE 3 MONOTHERAPY STUDY WITH MAINTENANCE PERIOD TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Recruiting·Pfizer·Phase 3·NCT07783425·1,375 enrolled

A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED PHASE 3 COMBINATION THERAPY STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE OR OLDER WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

Recruiting·Pfizer·Phase 3·NCT07765888·375 enrolled

COPD1 trial

A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF TILREKIMIG IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Not yet recruiting·Pfizer·Phase 3·NCT07839884·1,360 enrolled

Unspecified1 trial

A RANDOMISED, PHASE 1, OPEN-LABEL, SINGLE-DOSE, STUDY TO EVALUATE THE PHARMACOKINETICS AND TOLERABILITY OF TILREKIMIG IN HEALTHY PARTICIPANTS WHEN CO-MIXED WITH RHUPH20 AS A SUBCUTANEOUS INJECTION

Active, not recruiting·Pfizer·Phase 1·NCT07792941·12 enrolled

Details

Drug Info

Related News